|
| Press Releases |
|
 |
|
| Monday, August 11, 2025 |
|
|
Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products |
| Cryofocus Medtech (Shanghai) Co., Ltd. ("Cryofocus" or the "Company," Stock Code: 6922.HK), a global innovator in minimally invasive interventional cryotherapy, last friday announced its unaudited interim results for the six months ended June 30, 2025. more info >> |
|
|
康灃生物中期業績創紀錄 呼吸介入產品驅動收入激增162% |
| 專注於微創介入冷凍治療領域的創新醫療器械公司康灃生物科技（上海）股份有限公司（「康灃生物」或「公司」，股份代號：6922.HK）公布其截至2025年6月30日止六個月的中期業績。 more info >> |
|
| Tuesday, April 1, 2025 |
|
|
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024 |
| Cryofocus Medtech (Shanghai) Co., Ltd. ('Cryofocus Medtech' or the 'Company', stock code: 6922.HK), announced its annual results for the year ended 31 December 2024 (the 'Reporting Period'). more info >> |
|
|
康沣生物2024年收入及毛利稳步增加 持续坚定研发投入 |
| 专注于微创介入冷冻治疗领域的中国创新医疗器械公司康沣生物科技(上海)股份有限公司(“康沣生物”或“公司”，股份代号；6922.HK)，公布其截至2024年12月31日止年度(“报告期”)业绩。 more info >> |
|
|
康灃生物2024年收入及毛利穩步增加 持續堅定研發投入 |
| 專注於微創介入冷凍治療領域的中國創新醫療器械公司康灃生物科技(上海)股份有限公司(「康灃生物」或「公司」，股份代號；6922.HK)，公佈其截至2024年12月31日止年度(「報告期」)業績。2024年，康灃生物實現總營收5,350萬元(人民幣，下同)，同比增長30.7%，主要受心臟冷凍消融系統、冷凍黏連治療系統及其他呼吸介入產品的銷量增加所帶動。報告期內，毛利同比增加23.7%至達3,840萬元，毛利率約71.8%。 more info >> |
|
| Tuesday, December 12, 2023 |
|
|
康沣生物心脏冷冻消融系统获NMPA批准上市 |
| 专注于微创介入冷冻治疗领域的中国创新医疗器械公司——康沣生物科技（上海）股份有限公司（以下简称「公司」或「康沣生物」，6922.HK）发布自愿性公告，公司自主开发的心脏冷冻消融系统已获中国国家药品监督管理局（NMPA）批准上市。 more info >> |
|
|
康灃生物心臟冷凍消融系統獲NMPA批准上市 |
| 專注於微創介入冷凍治療領域的中國創新醫療器械公司——康灃生物科技（上海）股份有限公司（以下簡稱「公司」或「康灃生物」，6922.HK）發佈自願性公告，公司自主開發的心臟冷凍消融系統已獲中國國家藥品監督管理局（NMPA）批准上市。 more info >> |
|
|
Cryofocus Medtech Obtains NMPA Approval for the AF Cryoablation System |
| The innovative medical device company in China with a main focus on the field of minimally-invasive interventional cryotherapy more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
卓正醫療上市在即：認購火爆 以獨特商業模式撬動業績逆勢增長
Feb 5, 2026 14:24 HKT/SGT
|
|
|
卓正医疗上市在即：认购火爆 以独特商业模式撬动业绩逆势增长
Feb 5, 2026 14:24 HKT/SGT
|
|
|
Annature Launches 21 CFR Part 11 Compliant Digital Signatures to Support FDA-Regulated Organisations
Feb 5, 2026 13:00 HKT/SGT
|
|
|
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States
Feb 5, 2026 12:54 HKT/SGT
|
|
|
Goldenstone Acquisition Limited (Ticker: GDST) Announces Intent to Merge with ESG Packaging Innovator Deluxe Technology Group, Targeting 2026 NASDAQ Listing
Feb 5, 2026 12:53 HKT/SGT
|
|
|
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 5, 2026 11:55: JST
|
|
|
SuperX Strengthens Japan Presence to Explore AI Data Center Projects with Local Partners
Feb 5, 2026 11:00 HKT/SGT
|
|
|
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 5, 2026 10:55 HKT/SGT
|
|
|
雲頂新耀宣佈與麥科奧特達成MT1013獨家商業化許可協議
Feb 5, 2026 10:55 HKT/SGT
|
|
|
云顶新耀宣布与麦科奥特达成MT1013独家商业化许可协议
Feb 5, 2026 10:55 HKT/SGT
|
|
|
Hitachi significantly expands exhibits at the "Hitachi Building Solutions Lab", a research facility for collaborative creation with customers
Feb 5, 2026 11:48 JST
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES, 체외 진단약 등 각종 검사 키트 위탁 제조를 위한 토탈 솔루션 체계 구축
Feb 5, 2026 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES在接受委託製造體外診斷試劑等各種檢驗套組中 確立綜合式的解決方案體制
Feb 5, 2026 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES在体外诊断试剂等的各种检测试剂盒的受托制造中 确立全面解决方案体制
Feb 5, 2026 10:00 HKT/SGT
|
|
|
愛格法醫療榮獲2026年KLAS(R)評鑑美國三大企業影像領域最佳供應商殊榮
Feb 5, 2026 05:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
